Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
Fracasso
P M
PM
Tan
B R
BR
Grieff
M
M
Stephenson
J
J
Liapis
H
H
Umbeck
N L
NL
Von Hoff
D D
DD
Rowinsky
E K
EK
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001996:Bronchopneumonia / Q000150:complications; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D015432:Glomerulonephritis, Membranoproliferative / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine